natgillin/translations-raw huggingface dataset:
The rapid introduction in the 1970s of high-fructose corn syrup into the food supply, particularly in soft drinks, has been recognized as an important factor contributing to the obesity epidemic that has swept the world in the last 30 years. 
Naglo uvođenje kukuruznog sirupa s visokim sadržajem fruktoze u prehrambene proizvode 1970-tih godina, napose u bezalkoholna pića, pokazalo se važnim čimbenikom koji je doprinio pojavi debljine epidemijskih razmjera u zadnjih 30 godina.
Accordingly, the invention provides a composition for use in preventing or treating allergy to cats by tolerisation comprising four or more different polynucleotide sequences which when expressed cause the production of a composition for use in preventing or treating allergy to cats by tolerisation comprising: 
Sastav, naznačen time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od sekvenci polinukleotida koje kada se iskazuju uzrokuju proizvodnju sastava kao što je definirano u bilo kojem zahtjevu 1 do 3.
a heavy chain variable domain having all three complementarity determining regions (CDRs) of the variable domain of SEQ ID NO: 1; and 
VQLQQSGAELKKPGASVKVSCKASGYTFTEYIIHWIKLRSGQGLEWIGWFYP GSNDIQYNAQFKGKATLTADKSSSTVYMELTGLTPEDSAVYFCARRDDFSGY DALPYWGQGTLVTVSA (SEQ ID NO:1), pri čemu navedena varijabilna domena može proizvoljno nadalje sadržavati Q ostatak na njegovom N-terminalnom kraju;
repeating steps (b) and (c) until at least 80% of the protein component is incorporated into lipoprotein complexes, thereby forming lipoprotein complexes. 
ponavljanje koraka (b) i (c) sve dok se najmanje 80% proteinske komponente ne ugradi u lipoproteinske komplekse, te tako nastaju lipoproteinski kompleksi.
Conduit 14 and Nozzle 12 
Cjevovod 14 1 mlaznica 12
wherein the method comprises treating a compound of formula (8): or a pharmaceutically acceptable salt thereof, with a compound of formula (9): or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof. 
No o Lo OH ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
(a′) reacting a compound of formula 4: 
(a') reakcije spoja prema formuli 4:
The cellulose ether film of claim 1, wherein the cellulose ether film has a water vapor transmission rate (WVTR) of about 160 g/m2/day or less, wherein the water vapor transmission rate (WVRT) is a value measured using Water method in which a cup filled with a predetermined amount of water was tightly covered with the cellulose ether film, and then left at 25 °C and 5% relative humidity (RH) for 24 hours, followed by calculating an amount of evaporated water as WVRT. 
Film od celuloznog etera iz patentnog zahtjeva 1, gdje film od celuloznog etera ima brzinu prijenosa vodene pare (WVTR - water vapor transmission rate) od oko 160 g/m"/danu ili manju, gdje je brzina prijenosa vodene pare (WVTR) vrijednost izmjerena korištenjem vodene metode u kojoj je čaša napunjena sa unaprijed određenom količinom vode čvrsto prekrivena filmom od celuloznog etera, i zatim ostavljena na 25%C i 5% relativne vlažnosti (RH - relative humidity) tokom 24 sata, nakon čega je izračunata količina isparene vode kao WVRT.
the blade carrier is operably positioned in the interior volume of the housing and constructed and arranged to be adjustable in at least a first position and second position; 
nosač oštrica (30) je radno smješten u unutarnjem volumenu (42) kućišta (40) i takve konstrukcije i smještaja da se može podesiti u najmanju ruku prvom položaju i drugom položaju;
In some embodiments, compounds of the invention increase activity of the RUP25 receptor. 
U nekim oblicima, spojevi izuma povećavaju aktivnost RUP25 receptora.
A plurality of hollow spherical glass particles of any one of claims 1 to 7. 
Više šupljih sferničnih staklenih čestica sukladno bilo kojem od patentnih zahtjeva 1 do 5.
The method of claim 12, wherein said administration is to be repeated at least two, three, four, five, six, seven, eight, nine of ten times, after determination of a MRD negative status. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedenu primjenu treba ponoviti najmanje dva, tri, četiri, pet, šest, sedam, osam, devet ili deset puta, nakon što se odredi status negativnosti na MRD.
The fusion peptide according to claim 9 or 10, wherein component (III) comprises at least 4, preferably at least 10, more preferably at least 20 amino acid residues of the N-terminal sequence of GLP-2 as in proglucagon or of GLP-1(7-37). 
Fuzijski peptid prema patentnom zahtjevu 9 ili 10, naznačen time da komponenta (III) obuhvaća najmanje 4, poželjno najmanje 10, a još poželjnije najmanje 20 aminokiselinskih ostataka N-terminalne sekvence od GLP-2 kao u proglukagonu ili od GLP-1(7-37). t>&
Particularly suitable solvents include methanol, ethanol, 1-propanol, 2-propanol, 2-methyl-2-propanol, acetonitrile, tetrahydrofurane, 1,4-dioxane and acetone and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se organsko otapalo odabire iz skupine koja se sastoji od metanola, etanola, 1-propanola, 2-propanola, 2-metil-2-propanola, acetonitrila, tetrahidrofurana, 1,4-dioksana i njihovih mješavina.
One such method involves relating incident laser power arriving at the incident surface (Pi) to the laser power transmitted through the material (Pt) i.e. emerging from the opposite surface, in the relationship: 
Jedan takav postupak uključuje odnos upadne snage lasera koji dolazi na površinu upadanja (Pi) prema snazi lasera koji se prenosi kroz materijal (Pt), to jest koji izlazi na suprotnoj površini, u relaciji:
The pharmaceutical composition according to any of claims 1 - 4, wherein the ionic surfactant is an anionic surfactant selected from the group consisting of sodium or potassium dodecyl sulfate, sodium octadecylsulfate, sodium bis(2-ethylhexyl)sulfosuccinate (AOT), and a combination thereof. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 4, pri čemu je ionski surfaktant anionski surfaktant odabran iz skupine sastavljene od natrijevog ili kalijevog dodecil sulfata, natrij oktadecilsulfata, natrij bis(2- etilheks1l)-sulfosukcinata (AOT), i njihove kombinacije.
The compound of claim 1, wherein the compound has formula VIII 
Spoj sukladno zahtjevu 1, pri čemu spoj ima formulu VIII
Use of a compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers; for the preparation of a medicament for the treatment of a disorder or disease, wherein the disorder or the disease is selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia. 
Uporaba spoja formule (I) prema bilo kojem od zahtjeva 1 do 4, ili njegove farmaceutski prihvatljive soli; ili njegovog optičkog izomera; ili mješavine optičkih izomera; naznačena time, da je za proizvodnju lijeka za liječenje poremećaja ili bolesti, pri čemu je poremećaj ili bolest odabrana iz skupine koju čine hiperlipidemija, arterioskleroza, = ateroskleroza, = periferalna - vaskularna bolest, = dislipidemija, - hiperbetalipoproteinemija, hipoalfalipoproteinemija,
Patent document 1: European Patent Application Publication No. 0850948 
10.01.2006. Broj europske prijave patenta:
The method of Claim 2 further comprising a preparation of the compound of formula (6), wherein the method comprises treating a compound of formula (5): or a pharmaceutically acceptable salt thereof, with an aldehyde under suitable conditions to form the compound of formula (6), or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahtjevom 2, koji se dodatno sastoji u dobivanju spoja formule (6), naznačen time što se postupak sastoji u obradi spoja formule (5): HR P20140486 T1 ili njegove farmaceutski prihvatljive sol, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6), ili njegove farmaceutski prihvatljive soli.
A power point as claimed in claim 6, characterised by comprising a timed power supply for each second light source (26) corresponding to a non-activated insert. 
Točka napajanja u skladu s patentnim zahtjevom 1, naznačena time što sadrži vremenski regulirani izvor napajanja za svaki drugi izvor svjetla (26) koji odgovara na neaktivirani umetak.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of panic disorder. 
U daljnjoj verziji, ovaj izum se odnosi i na uporabu spoja formule I za pripravu lijeka za liječenje poremećaja panike.
A cylinder lock and key system according to claim 1, wherein the key blades exhibit two mutually opposing sides (204, 206, 1004, 1006, 1104, 1106) and two mutually opposing edges (208, 210, 1008, 1010, 1108, 1110) joining the opposing sides and wherein the first stop surfaces (212a, 212b, 1012a, 1012b, 1112a, 1112b) are arranged at or in proximity to a common first edge (210, 1010, 1110). 
Sustav cilindar brave 1 ključa prema zahtjevu 1, naznačen time što oštrice ključa imaju dvije međusobno suprotne strane (204, 206, 1004, 1006,1104, 1106) i dva međusobno suprotna ruba (208, 210, 1008, 10 10, 1108, 1110) koji spajaju suprotne strane i pri čemu su prve zaustavne površine (212a, 212b, 10 12a, 10 12b, 11124, 1112b) raspoređene na ili u blizimi zajedničkog prvog ruba (210, 1010, 1110).
The method according to any one of claims 1 to 6, wherein culturing the one or more cells comprises batch cultivation of the cells or comprises continuous cultivation of the cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se uzgoj jedne ili više stanica sastoji u: šaržnom uzgoju stanica; ili
the interior mechanism (34, 35) for interrupting the air flow is realised as a spring-mounted or at least partly elastic roller (41) or as a spring-mounted roller mechanism whereby the roller has elevations that engage at least party positively into the holes (17, 18, 19, 20). 
Srce za sijanje u skladu sa patentnim zahtjevom 9, naznačeno time da je unutrašnji mehanizam (34) za prekidanje toka zraka realiziran kao valjak koji je montiran na oprugu ili barem djelomično elastičan valjak (41) ili kao mehanizam sa valjkom koji je montiran na oprugu gdje valjak ima elevacije koje se angažiraju barem djelomično pozitivno u rupe (17,18,19,20).
A compound according to claim 1, wherein the compound is 3,4-dihydroxy-4'-methylbiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, daje spoj 3,4-dihidroksi-4'-metilbifenil-2,6-dikarbonitril.
Compounds of formulae (I) and (II), in free or salt form, are antagonists of the G-protein-coupled chemoattractant receptor CRTh2, expressed on Th2 cells, eosinophils and basophils. 
Spojevi formula (I) i (11), u slobodnom obliku ili u obliku soli, su antagonisti s G-proteinom povezanog kemoatraktanta receptora CRTh2, koji se ekspresionira na stanicama Th2, eozinofilima i bazofilima.
Modular elements as claimed in claim 1, characterised in that the cover tile (84) is closed upperly by a cover element (102) at least partly transparent to solar radiation and defining with the cover tile (84) a seat for a capturing element (92) through which a thermovector fluid can circulate. 
Modularni elementi u skladu s patentnim zahtjevom 1, naznačeni time što je crijep za prekrivanje (84) zatvoren s gornje strane s elementom za pokrivanje (102), koji element za prekrivanje je barem djelomično proziran za sunčevo zračenje, i sa crijepom za prekrivanje (84) određuje ležište za element za skupljanje (92) kroz koji cirkulira fluid koji provodi toplinu,
Mill (20) according to any one of Claims 4 or 5, wherein the side wall (24) is shaped so as to follow precisely the profile of the grinding volumes (28). 
Mlin (20) sukladno bilo kojem od zahtjeva 2 1l1 3, pri čemu je bočni zid (24) oblikovan tako da precizno prati profil volumena za mljevenje (28).
A composition comprising trazodone, bupropion, and a pharmaceutically acceptable carrier for use in the treatment of female sexual dysfunction (FSD). 
Pripravak koji sadrži trazodon, bupropion, te farmaceutski prihvatljiv nosač za uporabu za liječenje ženske seksualne disfunkcije (FSD).
The second laser engraved image may correspond to the first image. Moreover, the first image could be a portrait of a human face. 
Sklop za identifikaciju prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je na prvoj slici (19) ljudsko lice.
In addition to increasing the temperature, this can be facilitated by making the ambient pressure low enough so that evaporation occurs more rapidly. 
Osim povišenja temperature, to se može olakšati i spuštanjem tlaka okoline u mjeri koja je dovoljna da se isparavanje odvija mnogo brže.
The ether extract was dried (MgS04), filtered and evaporated under vacuum to an oil. 
Eterski ekstrakt se suši (MgSO,), filtrira i ispari u vakuumu do ulja.
A formulation for personal hygiene in the form of O/W emulsion with a pH from 5.5 to 6.5, free of surfactants except for comprising an emulsifier consisting of a fatty alcohol having from 14 to 22 carbon atoms or of Glyceryl Stearate or a mixture thereof, which formulation further comprises Coco Caprylate and/or Coco Caprylate/Caprate, vitamin E or an ester thereof in an amount of 2.0 to 15% by weight on the total weight of the formulation, and Melaleuca alternifolia oil. 
HR P20190493 T1 PATENTNI ZAHTJEVI Formulacija za osobnu higijenu u obliku ulje/voda emulzije s pH od 5.5 do 6.5, bez surfaktanata osim što sadrži emulgator koji se sastoji od masnog alkohola koji ima 14 do 22 atoma ugljika ili gliceril stearata ili njihove smjese, pri čemu ta formulacija dalje sadrži koko kaprilat i/ili koko kaprilat/kaprat, vitamin E ili njegov ester u količini od 2.0 do 15 težinskih % na ukupnu težinu formulacije i ulje Melaleuca alternifolia.
A third embodiment provides a process for the preparation of a compound of formula (IV): 
1. = Postupak za pripremu spoja predstavljenog formulom (V):
The amount of modified starch in the coating composition is preferably from about 15% to about 40%, especially from about 15% to about 35% by dry weight. 
Postupak za proizvodnju prehrambenog proizvoda prema patentnom zahtjevu 1, naznačen time što je količina modificiranog škroba u kompoziciji smjese za pohanje 15 do 35% prema suhoj težini.
The method according to claim 55, wherein said fatty liver diesase is non-alcoholic fatty liver disease (NAFLD). 
Lipidni pripravak prema zahtjevu 42, naznačen time da navedena bolest masne jetre je nealkoholna bolest masne jetre (NAFLD).
A method of treating heart failure in a patient in need thereof, comprising administering to said patient an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein: the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4, and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6, and said non-naturally encoded amino acid is substituted in said A chain polypeptide at residue 1; and 
Modificirani polipeptid relaksina koji sadrži ne-prirodno kodiranu aminokiselinu, gdje: (a) polipeptid relaksina sadrži polipeptid A lanaca relaksina sa SEQ ID NO: 4 i polipeptid B lanca relaksina sa SEQ ID NO: 5 ili SEQ ID NO: 6 supstituiran sa ne-prirodno kodiranom aminokiselinom na poziciji odabranoj iz grupe koja se sastoji od: ostatka 1 lanca A, ostatka 5 lanca A, ostatka 13 lanca A, ostatka18 lanca A, i ostatka 7 lanca B; 1 (b) ne-prirodno kodirana aminokiselina je para-acetil-fenilalanin koja je po izboru povezana sa veznikom, polimerom, polimerom topivim u vodi, ili biološki aktivnim molekulom.
In yet another aspect of the invention inflammatory conditions and immune disorders to be treated by the compounds of the invention are chosen from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel conditions, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, coronary infarct damage, chronic inflammation, endotoxin shock, and smooth muscle proliferation disorders. 
SICA. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uvcitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, oštećenje nakon koronarnog infarkta, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
a generally tubular proximal housing part having opposite proximal and distal ends, wherein the proximal housing part is releasably connected to the distal housing part, wherein engagement between a first and a second fastener allows the proximal housing part to be releasably connected to the distal housing part, the distal end of the proximal housing part further comprising a fourth mechanically coded interface device; a medicament container having a slidable stopper arranged inside the medicament container prior to positioning the medicament container within the proximal housing part; 
općenito cjevasti proksimalni dio kućišta (120) koji ima nasuprotne proksimalne i distalne krajeve i koji u rastavljivo spojeni na navedeni distalni dio kućišta, pri čemu su četvrta mehanički kodirana sredstva sučelja (122) smještena na njegovom distalnom kraju; spremnik za lijek (40) koji ima klizni graničnik, pri čemu je navedeni spremnik postavljen da bude smješten unutar navedenog proksimalnog dijela kućišta; sklop spremnika za lijek sadrži navedeni spremnik za lijek postavljen unutar proksimalnog dijela kućišta;
Alternative Binding Assay Procedure 
D. Alternativni postupak ispitivanja vezivanja
This is performed with a device such as that shown in Fig. 2. 
To se izvodi uz pomoć takvog uređaja kakav je prikazan na slici 2.
Next the organic partition was washed with brine then dried over sodium sulfate before it was concentrated to approximately 5mL. 
Nakon toga je organski dio bio ispran sa slanom vodom i osušen iznad natrij sulfata prije nego što je bio koncentriran do približno 5 mL.
precipitation of the solid and drying same to obtain the dual-acting compound. 
(via) pospješivanja taloženja krutine te sušenja iste u svrhu dobivanja spoja dvostrukog djelovanja.
when the effective coefficient flag indicates that at least one non-zero transformation coefficient exists in the current second sub residual block, obtaining transformation coefficients of the current sub residual block based on a significance map indicating a location of the non-zero transformation coefficient in the current sub residual block and level information of the non-zero transformation coefficient in the current sub residual block obtained from the bitstream; 
kada zastavica kodiranog bloka označava da rezidualni blok transformacije sadrži barem jedan efektivni koeficijent transformacije koji nije nula, dobivanje koeficijenata transformacije prve jedinice frekvencijskog pojasa na temelju karte značajnosti koja ukazuje na mjesta efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa i informacije o razini efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa dobivenoj iz toka bitova;
characterised in that the solvent system comprises a mixture of polar solvents, wherein the mixture of polar solvents comprises a straight or branched chain aliphatic alcohol with 1 to 5 carbon atoms and an aliphatic nitrile with 1 to 3 carbon atoms, wherein the aliphatic nitrile is present at between 40% to 70% of the solvent system. 
(iii) dovođenje smjese iz koraka (1i) u doticaj s vodikom; naznačen time što sustav otapala sadrži smjesu polarnih otapala, gdje ta smjesa polarnih otapala obuhvaća alifatske alkohole ravnog ili razgranatog lanca s 1 do 5 atoma ugljika i alifatski nitril s 1 do 3 atoma ugljika.
The glue can be sprayed onto the wrapper to form dots of glue, e.g. at least at the ends of the wrapper and also in intermediate positions (in particular when a wrapped smoking article rod is cut into several pieces afterwards). 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se ljepilo nanese sprejanjem na omot (2), kako bi se stvorile točke ljepila, poželjno barem na krajevima omota (2).
A second aspect of the present invention relates to a solid support for cultivation of anchorage-dependent cells recycled according to a method of the present invention. 
Drugi aspekt ovoga izuma se odnosi na krute potpore za uzgoj stanica koje potrebuju pričvršćivanje, a koje su reciklirane sukladno postupku iz ovoga izuma.
The UVR indicator according to claim 9 wherein the second prompt UVB and/or UVA radiation sensitive material may change characteristic, such as change colour in response to a first initial dose/level of UVB and/or UVA radiation and the first delayed UVB and/or UVA radiation sensitive material may change characteristic, such as colour in response to an increased dose of UVB and/or UVA radiation, and optionally wherein changes in colour can be visualised separately by way of discrete areas of said first and second UVB and/or UVA radiation sensitive material, and optionally wherein when the first and second UVB and/or UVA radiation sensitive materials are printed on top of one another, the colour changes being varied progressively, and optionally wherein the substrate is coloured so as to match/correspond to an initial colour or altered colour of the ink and in this way the ink can be printed in a particular manner so as to reveal or obscure an image in response to UVB and/or UVA radiation. 
Indikator UV zračenja prema zahtjevu 9 naznačen time da drugi trenutni materijal koji je osjetljiv na UVB i/ili UVA zračenje može mijenjati karakteristiku, kao što je promjena boje kao odgovor na prvu početnu dozu/razinu UVB i/ili UVA zračenja i prvi odgođeni materijal koji je osjetljiv na UVB i/ili UVA zračenje može mijenjati karakteristiku, kao što je promjena boje kao odgovor na povišenu dozu UVB i/ili UVA zračenja, i proizvoljno pri čemu se promjene boje mogu vizualizirati odvojeno pomoću diskretnih područja, navedenog prvog i drugog materijala koji je osjetljiv na UVB 1/ili UVA zračenje, i proizvoljno pri čemu kada su prvi i drugi materijal koji je osjetljiv na UVB i/ili UVA zračenje otisnuti jedan povrh drugoga, promjene boje se mijenjaju postupno, i proizvoljno pri čemu je podloga obojena tako da se slaže/odgovara početnoj boji ili promijenjenoj boji tinte i na ovaj način se tinta može ispisati na poseban način kako bi se otkrilo ili zamaglilo sliku kao odgovor na UVB i/ili UVA zračenje.